Mark J. Bachleda, Pharm.D., M.B.A.

Mark J. Bachleda, Pharm.D., M.B.A., has served as a member of our board of directors since June 2025. Since June 2024, Dr. Bachleda has served as the Chief Executive Officer and member of the Board of Directors of Eyconis, Inc. Previously, Dr. Bachleda has served in executive leadership roles at Amgen, Juno Therapeutics and Bristol Myers Squibb (BMS), and most recently he was Chief Commercial Officer at Galera Therapeutics. Prior to joining Galera, he served as Vice President and U.S. Business Unit Head of the CAR T cell therapy franchise at BMS, a role he held previously at Celgene Corporation before its acquisition by BMS in 2019. Prior to this, he was Vice President, Sales and Account Management at Juno when it was acquired by Celgene in 2018. Previously, he had a 15-year career at Amgen in U.S. and international roles of increasing responsibility up to Country President and General Manager of Amgen Czech Republic. Earlier in his career, he held positions at Pfizer, Inc. and Johnson & Johnson. Dr. Bachleda is a registered pharmacist and received his Pharm.D. degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned MBA degrees from both Columbia University and the University of California, Berkeley.